Coinbase is poised to benefit from U.S. spot ether ETFs, if they’re approved, according to JMP Securities. Expectations for the potential approval of proposed exchange traded funds tracking spot ether grew this week — a reversal from widespread consensus that the Securities and Exchange Commission was unlikely to approve them — based on the lack of engagement by the agency on the filings. The turnaround sent ether soaring more than 20% to start the week. ETH.CM= 5D mountain Ether 5-day chart JMP’s Devin Ryan said Coinbase could see benefits to its transaction, custody and staking businesses as a result of the introduction of ether ETFs, in a note Wednesday. “For Coinbase … we estimate that with a spot-Ethereum ETF approval, the end effect is that more capital will flow into the broader industry, and accordingly, we do not see this as cannibalistic to the existing business model,” JMP’s Devin Ryan said in a note Wednesday. “It is effectively removing barriers that previously existed for certain pools of capital.” “Perhaps even more so we anticipate that demand around usage of underlying ETH should accelerate as more capital flows into the network and more development occurs on top of it, which could drive an even greater acceleration of volume and demand in the spot market relative to ETF demand,” Ryan added. He highlighted that Coinbase’s own blockchain, Base, operates on the Ethereum network. He also said an ether ETF approval doesn’t necessarily signal a blessing by the SEC of the broader crypto asset class, or even comfort around all ETH use-cases, such as staking. Nevertheless, an approval could still set a precedent that “in many participants’ eyes serves to de-risk their involvement” with crypto. JMP has an outperform rating on Coinbase and a price target of $320, implying nearly 42% upside from Tuesday’s close. Shares are up more than 33% year to date. COIN YTD mountain COIN year to date Final decisions on applications by VanEck and Ark Invest are due this Thursday and Friday, respectively. BlackRock, Fidelity, Invesco, Grayscale and Bitwise Asset Management also have applications awaiting decisions this year.
.jpg?width=1200&width=1200&auto=webp&quality=75 "London trial could have groundbreaking implications for liver disease patients"){kind=small}
